Advice
Not recommended for use within NHS Scotland.
RECOMMENDATION
Although this is currently the only agent licensed for use in moderately severe to severe Alzheimer's disease, the magnitude of the effect is extremely small. Compared with placebo it is associated with a statistically significant reduction in the rate of deterioration in global, functional and cognitive scales. On the evidence presented, the associated gains appear to be marginal relative to the overall costs.
The license holder has indicated their decision to resubmit.
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- Memantine (Ebixa®)
- SMC ID:
- 57/03
- Indication:
- Moderately severe to severe Alzheimer's disease
- Pharmaceutical company
- Lundbeck Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 11 August 2003